Skip to main content

01.07.2013 | Systematic Review

Sulfonylureas and Risk of Falls and Fractures: A Systematic Review

verfasst von: Kate L. Lapane, Shibing Yang, Monique J. Brown, Rachel Jawahar, Caleb Pagliasotti, Swapnil Rajpathak

Erschienen in: Drugs & Aging | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Sulfonylureas have been linked to increased risk of hypoglycemia. Hypoglycemia may lead to falls, and falls may lead to fracture. However, studies quantifying the association between sulfonylureas and fractures are sparse and yield inconsistent results.

Objective

The purpose of this article was to review the literature regarding sulfonylurea use and falls or fall-related fractures among older adults with type 2 diabetes mellitus and to delineate areas for future research.

Data Sources

We searched MEDLINE (1966–March 2012) and CINAHL (1937–March 2012) for studies of patients with type 2 diabetes mellitus living in the community or nursing homes.

Study Selection

The search algorithms combined three domains: (1) diabetic patients, (2) sulfonylurea medications, and (3) fractures or falls. We included only publications in English that pertained to human subjects. We found 9 randomized trials and 12 non-experimental studies that met the inclusion criteria.

Study Appraisal and Synthesis Methods

The guidelines provided by the Cochrane handbook or Agency for Healthcare Research and Quality (AHRQ) Methods Guide are too general to distinguish the quality of included non-experimental studies, so we developed several specific domains based on those general guidelines. These domains included study design, study population, follow-up time, comparison group, exposure definition, outcome definition, induction period, confounding adjustment, and attrition or missing data. The data were not amenable to a meta-analysis.

Results

No clinical trials included fracture as a primary endpoint. Most clinical trials excluded older adults. Most studies were not designed to evaluate the risk of sulfonylureas on fractures or falls. Studies did not show an increased risk of falls/fractures with sulfonylurea.

Limitations

The data available from existing studies suffer from methodological limitations including insufficient events, lack of primary endpoints, exclusion of older adults, and lack of clarity or inappropriate comparison groups.

Conclusion

Future studies are needed to appropriately estimate the effect of sulfonylureas on falls or fall-related fractures in older adults who are at increased risk for hypoglycemia, the hypothesized mechanism for fractures related to sulfonylurea therapy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ben Salem C, Fathallah N, Hmouda H, et al. Drug-induced hypoglycaemia: an update. Drug Saf. 2011;34(1):21–45.PubMedCrossRef Ben Salem C, Fathallah N, Hmouda H, et al. Drug-induced hypoglycaemia: an update. Drug Saf. 2011;34(1):21–45.PubMedCrossRef
2.
Zurück zum Zitat Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602–13.PubMedCrossRef Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602–13.PubMedCrossRef
3.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.CrossRef UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.CrossRef
4.
Zurück zum Zitat Wright AD, Cull CA, Macleod KM, on behalf of UKPDS Group, et al. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications. 2009;20(6):395–401.CrossRef Wright AD, Cull CA, Macleod KM, on behalf of UKPDS Group, et al. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications. 2009;20(6):395–401.CrossRef
5.
Zurück zum Zitat Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168(8):820–5.PubMedCrossRef Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168(8):820–5.PubMedCrossRef
6.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48(7):1292–9.PubMedCrossRef Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48(7):1292–9.PubMedCrossRef
7.
Zurück zum Zitat Melton LJ, Leibson C, Achenbach S, et al. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008;23(8):1334–42.PubMedCrossRef Melton LJ, Leibson C, Achenbach S, et al. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008;23(8):1334–42.PubMedCrossRef
8.
Zurück zum Zitat Cheung BM, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122(5):443–53.PubMedCrossRef Cheung BM, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122(5):443–53.PubMedCrossRef
9.
Zurück zum Zitat Dodd AH, Colby MS, Boye KS, et al. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999–2004. Curr Med Res Opin. 2009;25(7):1605–13.PubMedCrossRef Dodd AH, Colby MS, Boye KS, et al. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999–2004. Curr Med Res Opin. 2009;25(7):1605–13.PubMedCrossRef
10.
Zurück zum Zitat Ross PD, Davis JW, Vogel JM, et al. A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tissue Int. 1990;46(3):149–61.PubMedCrossRef Ross PD, Davis JW, Vogel JM, et al. A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tissue Int. 1990;46(3):149–61.PubMedCrossRef
11.
Zurück zum Zitat Looker AC, Melton LJ, Harris TB, et al. Prevalence and trends in low femur bone density among older US adults: NHANES 2005–2006 compared with NHANES III. J Bone Miner Res. 2010;25(1):64–71.PubMedCrossRef Looker AC, Melton LJ, Harris TB, et al. Prevalence and trends in low femur bone density among older US adults: NHANES 2005–2006 compared with NHANES III. J Bone Miner Res. 2010;25(1):64–71.PubMedCrossRef
12.
Zurück zum Zitat Ivers RQ, Cumming RG, Mitchell P, et al. Diabetes and risk of fractures: The Blue Mountains Eye study. Diab Care. 2001;24(7):1198–203.CrossRef Ivers RQ, Cumming RG, Mitchell P, et al. Diabetes and risk of fractures: The Blue Mountains Eye study. Diab Care. 2001;24(7):1198–203.CrossRef
13.
Zurück zum Zitat Rix M, Andreassen H, Eskildsen P. Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care. 1999;22(5):827–31.PubMedCrossRef Rix M, Andreassen H, Eskildsen P. Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care. 1999;22(5):827–31.PubMedCrossRef
14.
Zurück zum Zitat Vogt MT, Cauley JA, Kuller LH, et al. Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J Bone Miner Res. 1997;12(2):283–9.PubMedCrossRef Vogt MT, Cauley JA, Kuller LH, et al. Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J Bone Miner Res. 1997;12(2):283–9.PubMedCrossRef
15.
Zurück zum Zitat Sanada M, Taguchi A, Higashi Y, et al. Forearm endothelial function and bone mineral loss in postmenopausal women. Atherosclerosis. 2004;176(2):387–92.PubMedCrossRef Sanada M, Taguchi A, Higashi Y, et al. Forearm endothelial function and bone mineral loss in postmenopausal women. Atherosclerosis. 2004;176(2):387–92.PubMedCrossRef
16.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, on behalf of the PRISMA Group, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;21(339):b2535.CrossRef Moher D, Liberati A, Tetzlaff J, on behalf of the PRISMA Group, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;21(339):b2535.CrossRef
17.
Zurück zum Zitat Wright RW, Brand RA, Dunn W, et al. How to write a systematic review. Clin Orthop Relat Res. 2007;455:23–9.PubMedCrossRef Wright RW, Brand RA, Dunn W, et al. How to write a systematic review. Clin Orthop Relat Res. 2007;455:23–9.PubMedCrossRef
18.
Zurück zum Zitat Kitchenham B. Procedures for Performing Systematic Reviews. Keele (Staffs): Keele University, 2004 Jul. Report no.: TR/SE-040. Kitchenham B. Procedures for Performing Systematic Reviews. Keele (Staffs): Keele University, 2004 Jul. Report no.: TR/SE-040.
19.
Zurück zum Zitat Kanazawa I, Yamaguchi T, Yamamoto M, et al. Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab. 2010;28(5):554–60.PubMedCrossRef Kanazawa I, Yamaguchi T, Yamamoto M, et al. Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab. 2010;28(5):554–60.PubMedCrossRef
20.
Zurück zum Zitat Bilik D, McEwen LN, Brown MB, et al. Thiazolidinediones and fractures: Evidence from translating research into action for diabetes. J Clin Endocrinol Metab. 2010;95(10):4560–5.PubMedCrossRef Bilik D, McEwen LN, Brown MB, et al. Thiazolidinediones and fractures: Evidence from translating research into action for diabetes. J Clin Endocrinol Metab. 2010;95(10):4560–5.PubMedCrossRef
21.
Zurück zum Zitat Douglas I, Evans S, Pocock S, et al. The risk of fractures associated with thiazolidinediones: A self-controlled case-series study. PLoS Med. 2009;6(9):e1000154.PubMedCrossRef Douglas I, Evans S, Pocock S, et al. The risk of fractures associated with thiazolidinediones: A self-controlled case-series study. PLoS Med. 2009;6(9):e1000154.PubMedCrossRef
22.
Zurück zum Zitat Dormuth CR, Carney G, Carleton B, et al. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009;169(15):1395–402.PubMedCrossRef Dormuth CR, Carney G, Carleton B, et al. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009;169(15):1395–402.PubMedCrossRef
23.
Zurück zum Zitat Yamamoto M, Yamaguchi T, Yamauchi M, et al. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009;24(4):702–9.PubMedCrossRef Yamamoto M, Yamaguchi T, Yamauchi M, et al. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009;24(4):702–9.PubMedCrossRef
24.
Zurück zum Zitat Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database. BMJ. 2009;3(339):b4731.CrossRef Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database. BMJ. 2009;3(339):b4731.CrossRef
25.
Zurück zum Zitat Solomon DH, Cadarette SM, Choudhry NK, et al. A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab. 2009;94(8):2792–8.PubMedCrossRef Solomon DH, Cadarette SM, Choudhry NK, et al. A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab. 2009;94(8):2792–8.PubMedCrossRef
26.
Zurück zum Zitat Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: A case-control study. Diabetes Care. 2008;31(2):199–203.PubMedCrossRef Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: A case-control study. Diabetes Care. 2008;31(2):199–203.PubMedCrossRef
27.
Zurück zum Zitat Huang ES, Karter AJ, Danielson KK, et al. The association between the number of prescription medications and incident falls in a multiethnic population of adult type-2 diabetes patients: The diabetes and aging study. J Gen Intern Med. 2010;25(2):141–6.PubMedCrossRef Huang ES, Karter AJ, Danielson KK, et al. The association between the number of prescription medications and incident falls in a multiethnic population of adult type-2 diabetes patients: The diabetes and aging study. J Gen Intern Med. 2010;25(2):141–6.PubMedCrossRef
28.
Zurück zum Zitat Göke B, Gallwitz B, Eriksson J, on behalf of the D1680C00001 Investigators, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial. Int J Clin Pract. 2010;64(12):1619–31.PubMedCrossRef Göke B, Gallwitz B, Eriksson J, on behalf of the D1680C00001 Investigators, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial. Int J Clin Pract. 2010;64(12):1619–31.PubMedCrossRef
29.
Zurück zum Zitat Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. Int J Clin Pract. 2010;64(5):562–76.PubMedCrossRef Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. Int J Clin Pract. 2010;64(5):562–76.PubMedCrossRef
30.
Zurück zum Zitat Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13(2):160–8.PubMedCrossRef Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13(2):160–8.PubMedCrossRef
31.
Zurück zum Zitat Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157–66.PubMedCrossRef Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157–66.PubMedCrossRef
32.
Zurück zum Zitat Kahn S, Zinman B, Lachin J, on behalf of the ADOPT Study Group, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31(5):845–51.PubMedCrossRef Kahn S, Zinman B, Lachin J, on behalf of the ADOPT Study Group, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31(5):845–51.PubMedCrossRef
33.
Zurück zum Zitat Home P, Pocock S, Beck Nielsen H, on behalf of the RECORD Study Team, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–35.PubMedCrossRef Home P, Pocock S, Beck Nielsen H, on behalf of the RECORD Study Team, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–35.PubMedCrossRef
34.
Zurück zum Zitat Nissen SE, Nicholls SJ, Wolski K, on behalf of the PERISCOPE Investigators, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–73.PubMedCrossRef Nissen SE, Nicholls SJ, Wolski K, on behalf of the PERISCOPE Investigators, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–73.PubMedCrossRef
35.
Zurück zum Zitat Jain R, Osei K, Kupfer S, et al. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy. 2006;26(10):1388–95.PubMedCrossRef Jain R, Osei K, Kupfer S, et al. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy. 2006;26(10):1388–95.PubMedCrossRef
36.
Zurück zum Zitat Hamann A, Garcia-Puig J, Paul G, et al. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes. 2008;116(1):6–13.PubMedCrossRef Hamann A, Garcia-Puig J, Paul G, et al. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes. 2008;116(1):6–13.PubMedCrossRef
37.
38.
Zurück zum Zitat Ligthelm RJ, Kaiser M, Vora J, et al. Insulin use in elderly adults: risk of hypoglycemia and strategies for care. J Am Geriatr Soc. 2012;60(8):1564–70.PubMedCrossRef Ligthelm RJ, Kaiser M, Vora J, et al. Insulin use in elderly adults: risk of hypoglycemia and strategies for care. J Am Geriatr Soc. 2012;60(8):1564–70.PubMedCrossRef
39.
Zurück zum Zitat Lamy PP. Physiological changes due to age: Pharmacodynamic changes of drug action and implications for therapy. Drugs Aging. 1991;1(5):385–404.PubMedCrossRef Lamy PP. Physiological changes due to age: Pharmacodynamic changes of drug action and implications for therapy. Drugs Aging. 1991;1(5):385–404.PubMedCrossRef
42.
Zurück zum Zitat Gurwitz JH. Polypharmacy: A new paradigm for quality drug therapy in the elderly. Arch Intern Med. 2004;164(18):1957–9.PubMedCrossRef Gurwitz JH. Polypharmacy: A new paradigm for quality drug therapy in the elderly. Arch Intern Med. 2004;164(18):1957–9.PubMedCrossRef
45.
Zurück zum Zitat Prybys KM. Deadly drug interactions in emergency medicine. Emerg Med Clin North Am. 2004;22(4):845–63.PubMedCrossRef Prybys KM. Deadly drug interactions in emergency medicine. Emerg Med Clin North Am. 2004;22(4):845–63.PubMedCrossRef
46.
Zurück zum Zitat Tinetti ME, Doucette J, Claus E, et al. Risk factors for serious injury during falls by older persons in the community. J Am Geriatr Soc. 1995;43(11):1214–21.PubMed Tinetti ME, Doucette J, Claus E, et al. Risk factors for serious injury during falls by older persons in the community. J Am Geriatr Soc. 1995;43(11):1214–21.PubMed
Metadaten
Titel
Sulfonylureas and Risk of Falls and Fractures: A Systematic Review
verfasst von
Kate L. Lapane
Shibing Yang
Monique J. Brown
Rachel Jawahar
Caleb Pagliasotti
Swapnil Rajpathak
Publikationsdatum
01.07.2013
Verlag
Springer International Publishing AG
Erschienen in
Drugs & Aging / Ausgabe 7/2013
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-013-0081-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.